Type 1 Diabetes News and Research

Latest Type 1 Diabetes News and Research

Catabasis Pharmaceuticals to advance program targeting type 2 diabetes with $39.6 million Series A financing

Catabasis Pharmaceuticals, a biopharmaceutical company developing novel therapeutics for the treatment of inflammatory and metabolic diseases, today announced it has completed a $39.6 million Series A financing led by SV Life Sciences, Clarus Ventures, and MedImmune Ventures. Also participating in the round is Advanced Technology Ventures.

21 Apr 2010

Investment report on Array BioPharma

MicroStockProfit.com announces an investment report featuring Array BioPharma Inc.. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

21 Apr 2010

Modest weight reduction reverses immune cell damage in obese people with diabetes

Australian scientists have shown for the first time that even modest weight loss reverses many of the damaging changes often seen in the immune cells of obese people, particularly those with Type 2 diabetes.

21 Apr 2010

Lotus Pharmaceuticals' asthma drug Laevo-Bambutero to receive Chinese SFDA Fast Track Approval

Lotus Pharmaceuticals, Inc., a growing developer, manufacturer and seller of medicine and drugs in the People's Republic of China reported that its asthma drug Laevo-Bambutero will receive the China's State Food & Drug Administration's (SFDA) Fast Track Approval to enter clinical trials. The SFDA's Drug Review and Evaluation Center told the Company during recent consultations at the end of the Company's IND that formal approval would be granted by the Beijing office of the SFDA.

21 Apr 2010

Forest Laboratories' fourth-quarter net sales up 11.0% to $995.6M

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that diluted earnings per share equaled $0.07 in the fourth quarter of fiscal 2010.

21 Apr 2010

ZenBio awarded Phase I SBIR grant to establish novel human cell-based models of NAFLD

ZenBio, Inc. announced that it has been awarded a Phase I SBIR grant to establish novel human cell-based models of non-alcoholic fatty liver disease (NAFLD) that will be useful for basic research and as a potential drug development platform. The project stems from recent efforts at ZenBio, Inc. to develop methods for differentiating adipose tissue derived progenitor cells into hepatocyte-like cells.

21 Apr 2010

Positive top-line results from Phenomix' Phase 3 trial of dutogliptin for Type 2 diabetes mellitus

Phenomix Corporation today announced positive top-line results from a six-month Phase 3 study comparing dutogliptin 400mg and 200mg once daily as monotherapy versus placebo for the treatment of patients with Type 2 diabetes mellitus. Dutogliptin is Phenomix' internally-discovered dipeptidyl peptidase-4 (DPP-4) inhibitor.

20 Apr 2010

Certain genetic mutations lead to Type 1 diabetes: The Scripps Research Institute

Scientists from The Scripps Research Institute have provided an answer to the 40-year-old mystery of how certain genetic mutations lead to Type 1 diabetes. This new molecular understanding could lead to novel therapies for Type 1 diabetes and other autoimmune diseases.

20 Apr 2010

Block by Block campaign to educate community, reduce impact of diabetes

It started with a simple medical survey in the Humboldt Park neighborhood on Chicago's near Northwest side whose results were reported in the Journal of Epidemiology in 2006.

20 Apr 2010

XOMA 052 antibody demonstrates potential for treatment of myeloma patients with elevated IL-6 levels

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that independent researchers presented results showing that XOMA's antibody to interleukin-1 beta (IL-1 beta), XOMA 052, was highly effective in reducing production of a protein that supports the proliferation of cancerous human myeloma cells in vitro.

20 Apr 2010

Canadian Diabetes Association recognizes world-class volunteers

In the spirit of National Volunteer Week, the Canadian Diabetes Association would like to send a sincere message of gratitude to the more than 35,000 community and professional volunteers who selflessly give their time each and every day to help advance the battle against diabetes.

20 Apr 2010

FDA-approved metformin can prevent tobacco-carcinogen induced lung tumors: Study

Metformin, a mainstay of treatment for patients with type 2 diabetes, may soon play a role in lung cancer prevention if early laboratory research presented here at the AACR 101st Annual Meeting 2010 is confirmed in clinical trials.

20 Apr 2010

Even modest weight loss brings many health benefits

There have been repeated warnings related to the growing obese and diabetes related population in Australia. Studies have shown that nearly 50% Australians are either obese or overweight and thus suffer from its ill effects like heart disease, high cholesterol and type II diabetes.

20 Apr 2010

Generex Biotechnology announces plan to obtain cost reimbursement coverage for Generex Oal-lyn

Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has established an action plan for obtaining cost reimbursement coverage for Generex Oal-lyn™, including the development of an insurance product that covers the costs of Generex Oral-lyn™ and any additional and/or comparable diabetes products.

19 Apr 2010

Laparoscopic sleeve gastrectomy receives health insurance coverage

The American Society for Metabolic and Bariatric Surgery (ASMBS) today announced its support of recent policy changes by Aetna Inc. and United Healthcare. The national health insurance giants will now cover laparoscopic sleeve gastrectomy, a newer method of bariatric surgery that is becoming increasingly popular as a treatment for morbid obesity.

19 Apr 2010

Amylin Pharmaceuticals announces $174.1M total revenue for first-quarter 2010

Amylin Pharmaceuticals, Inc. today reported financial results for the quarter ended March 31, 2010. The Company reported total revenue of $174.1 million for the quarter ended March 31, 2010, which includes net product sales of $172.3 million. Non-GAAP operating loss was $3.8 million for the quarter ended March 31, 2010, compared to $19.9 million for the same period in 2009.

19 Apr 2010

Racial disparities in sleep and health-related quality of life

A study in the April 15 issue of the Journal of Clinical Sleep Medicine shows that having a sleep disturbance is associated with clinically meaningful reductions in health-related quality of life, and the magnitude of this effect varies by race and sleep disorder.

17 Apr 2010

MU researchers determine efficient method for assessing body composition

Measuring body composition - the amount of fatty tissue, muscle tissue and bone present in the body - can provide valuable information for determining an individual's overall health status. However, obtaining accurate measurements can be difficult and expensive, according to Steve Ball, University of Missouri Extension fitness specialist.

17 Apr 2010

Diabetic mice generate new insulin-producing cells following extreme cell destruction

Type 1 diabetes is the most common cause of diabetes in children, although it may occur at any age. Also called juvenile diabetes, this pathology usually results from autoimmune destruction of insulin-producing cells of the pancreas.

16 Apr 2010

Calorie restriction may help people to lead longer and healthier lives

Organisms from yeast to rodents to humans all benefit from cutting calories. In less complex organisms, restricting calories can double or even triple lifespan. It's not yet clear just how much longer calorie restriction might help humans live, but those who practice the strict diet hope to survive past 100 years old.

16 Apr 2010

Type 1 Diabetes News and Research

Latest Type 1 Diabetes News and Research

Catabasis Pharmaceuticals to advance program targeting type 2 diabetes with $39.6 million Series A financing

Investment report on Array BioPharma

Modest weight reduction reverses immune cell damage in obese people with diabetes

Lotus Pharmaceuticals' asthma drug Laevo-Bambutero to receive Chinese SFDA Fast Track Approval

Forest Laboratories' fourth-quarter net sales up 11.0% to $995.6M

ZenBio awarded Phase I SBIR grant to establish novel human cell-based models of NAFLD

Positive top-line results from Phenomix' Phase 3 trial of dutogliptin for Type 2 diabetes mellitus

Certain genetic mutations lead to Type 1 diabetes: The Scripps Research Institute

Block by Block campaign to educate community, reduce impact of diabetes

XOMA 052 antibody demonstrates potential for treatment of myeloma patients with elevated IL-6 levels

Canadian Diabetes Association recognizes world-class volunteers

FDA-approved metformin can prevent tobacco-carcinogen induced lung tumors: Study

Even modest weight loss brings many health benefits

Generex Biotechnology announces plan to obtain cost reimbursement coverage for Generex Oal-lyn

Laparoscopic sleeve gastrectomy receives health insurance coverage

Amylin Pharmaceuticals announces $174.1M total revenue for first-quarter 2010

Racial disparities in sleep and health-related quality of life

MU researchers determine efficient method for assessing body composition

Diabetic mice generate new insulin-producing cells following extreme cell destruction

Calorie restriction may help people to lead longer and healthier lives

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Type 1 Diabetes News and Research

Latest Type 1 Diabetes News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in